Citigroup (C) Analysts Reiterate a “Buy” Rating on Endo Pharmaceuticals (ENDP)

Endo Pharmaceuticals (NASDAQ: ENDP)‘s stock had its “buy” rating reaffirmed by equities research analysts at Citigroup (NYSE: C) in a research note issued to investors on Tuesday. The analysts currently have a $48.00 price target on the stock.

Separately, analysts at Goldman Sachs (NYSE: GS) reiterated a “neutral” rating on shares of Endo Pharmaceuticals in a research note to investors on Wednesday, December 14th. Analysts at Credit Suisse (NYSE: CS) raised their EPS on shares of Endo Pharmaceuticals in a research note to investors on Tuesday, December 13rd. They now have a “neutral” rating and a $40.00 price target on the stock. Also, analysts at Zacks Investment Research reiterated a “neutral” rating on shares of Endo Pharmaceuticals in a research note to investors on Friday, November 11st. They now have a $34.00 price target on the stock.

Endo Pharmaceuticals Holdings Inc. is a specialty pharmaceutical company in pain management. The Company is engaged in the research, development, manufacturing, marketing and sales of branded and generic pharmaceutical products used primarily to treat and manage pain, overactive bladder, prostate and bladder cancer and central precocious puberty. Its portfolio of branded products includes Lidoderm, Opana ER and Opana, Percocet, Frova, Voltaren Gel, Vantas, Valstar and Supprelin LA. The Company concentrates on generics that have one or more barriers to market entry, such as complex formulation, regulatory or legal challenges or difficulty in raw material sourcing. During the year ended December 31, 2009, the branded products comprised approximately 91% of the Company’s net sales. In March 2009, Endo Pharmaceuticals Holdings Inc. completed the acquisition of Indevus Pharmaceuticals, Inc.

Shares of Endo Pharmaceuticals opened at 35.00 on Tuesday. Endo Pharmaceuticals has a 52 week low of $26.02 and a 52 week high of $44.53. The stock’s 50-day moving average is $33.6 and its 200-day moving average is $33.69. The company has a market cap of $4.089 billion and a price-to-earnings ratio of 17.40.